// App-Quantinova.ai

OR1‐003 : Anti‐CD27 enhances lymphoma immunotherapy through myeloid cell recruitment

Researchers

Presenter

  • A Turaj

Principal Investigators

  • V Field

  • C Chan

  • S James

  • K Cox

  • T Keler

  • P Johnson

  • A Al-Shamkhani

  • S Beers

  • M Glennie

  • M Cragg

  • S Lim

Medical Centers

  • Antibody and Vaccine Group, Cancer Sciences, University of Southampton, Southampton, United Kingdom

  • Celldex Therapeutics, Needham, United States

  • Cancer Sciences, University of Southampton, Southampton, United Kingdom

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Natural Killer cells

  • B-lymphocyte antigen CD20

  • Cyclin D1

  • Cytotoxic T-lymphocyte-associated protein 4

  • T-cell leukemia/lymphoma-1A

Drug/Treatment

  • Varlilumab

  • Rituximab

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved